Literature DB >> 2311440

Heterogeneity of beta-lactamase production in Pseudomonas maltophilia, a nosocomial pathogen.

W Cullmann1, W Dick.   

Abstract

Twenty Pseudomonas maltophilia isolates were examined for susceptibility to beta-lactam antibiotics, including carbapenems, and for beta-lactamase production. All the isolates were resistant to imipenem (MICs 64-512 mg/l) and to a lesser extent, to meropenem (MICs 16-256 mg/l). None of the isolates produced significant amounts of beta-lactamase without induction. Among the beta-lactams studied imipenem proved to be the most potent inducer; meropenem was a weaker inducer. Interestingly, 6-amino-penicillanic acid, even in concentrations up to 100 mg/l, entirely lacked induction activity. In any case enzyme production was drug concentration dependent and transient. Isoelectric focusing revealed 6 different enzymes distinguished by their different isoelectric points (pH 6.2, 8.3, 8.5, 9.0, 9.2 and 9.4). This suggested the lack of a unique beta-lactamase profile in P. maltophilia. Addition of 5 mM cyclic AMP (cAMP) or 0.5 mM cAMP-N6, O2-dioctanoyl (a lipophilic derivative) resulted in a marked drop of beta-lactamase induction by imipenem as compared to the control assay. Monitoring of carbapenem hydrolysis by cell-free supernatants revealed inactivation of both carbapenems. Meropenem was inactivated about 5 times more rapidly than imipenem. Our studies revealed that beta-lactamase production in P. maltophilia as well as growth kinetics were influenced to a considerable extent by the nutrient medium employed.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2311440     DOI: 10.1159/000238757

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  11 in total

Review 1.  Carbapenem-hydrolyzing beta-lactamases.

Authors:  B A Rasmussen; K Bush
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

Review 2.  Past and Present Perspectives on β-Lactamases.

Authors:  Karen Bush
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

3.  Characterization of the chromosomal aac(6')-Iz gene of Stenotrophomonas maltophilia.

Authors:  T Lambert; M C Ploy; F Denis; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

Review 4.  Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia.

Authors:  M Denton; K G Kerr
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

5.  Biochemical properties of inducible beta-lactamases produced from Xanthomonas maltophilia.

Authors:  R Paton; R S Miles; S G Amyes
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

Review 6.  Meropenem. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy.

Authors:  L R Wiseman; A J Wagstaff; R N Brogden; H M Bryson
Journal:  Drugs       Date:  1995-07       Impact factor: 9.546

7.  Rapid identification of metallo- and serine beta-lactamases.

Authors:  D J Payne; R Cramp; J H Bateson; J Neale; D Knowles
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

8.  In vitro activities of antimicrobial combinations against Stenotrophomonas (Xanthomonas) maltophilia.

Authors:  C D Poulos; S O Matsumura; B M Willey; D E Low; A McGeer
Journal:  Antimicrob Agents Chemother       Date:  1995-10       Impact factor: 5.191

9.  Phenotypic Heterogeneity Affects Stenotrophomonas maltophilia K279a Colony Morphotypes and β-Lactamase Expression.

Authors:  Ebrahim M Abda; Dagmar Krysciak; Ines Krohn-Molt; Uwe Mamat; Christel Schmeisser; Konrad U Förstner; Ulrich E Schaible; Thomas A Kohl; Stefan Nieman; Wolfgang R Streit
Journal:  Front Microbiol       Date:  2015-12-02       Impact factor: 5.640

Review 10.  The Current Burden of Carbapenemases: Review of Significant Properties and Dissemination among Gram-Negative Bacteria.

Authors:  Dalal Hammoudi Halat; Carole Ayoub Moubareck
Journal:  Antibiotics (Basel)       Date:  2020-04-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.